Intellectia LogoIntellectia
Stock
Crypto
Features
Resources
Company
Pricing
Sign inTry for Free
Intellectia Logo
Sign in
Intellectia Logo
StockCrypto

Features

Pre Market Movers
Financial AI Agent
Swing Trading
Stock Technical Analysis
Stock Monitor
Copy Top Investors Portfolio
Crypto Technical Analysis
Chart Pattern Signal

Resources

Blog
Earnings
Partner Program

Company

Contact
About
News Release
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. AMGN
    4. >
  4. Forecast

Stock Price Prediction

-
stocks logo
AMGN
-
$
0.000
0.000(0.000%)
    OverviewForecastTechnicalOptionsEarningsFinancialsValuationInsiders

AMGN Price Prediction Next Week

Based on the provided data and technical analysis, here is the price prediction for AMGN for next week:

Technical Analysis

  • Current RSI (14) at 56.75 indicates neutral momentum
  • MACD at 0.46 shows slightly bullish momentum
  • Price is trading below 200-day SMA ($300.90), indicating long-term bearish trend
  • Fibonacci support levels at $263.24 and resistance at $276.57

News Sentiment Analysis

  • Positive: High rating of 75% from Validea's Shareholder Yield Investor model
  • Positive: Strong cash return to shareholders through dividends and buybacks
  • Neutral: Recent options activity shows mixed sentiment with put/call contracts
  • Negative: Stock has underperformed broader market over past year

Price Target Prediction Based on technical indicators and news sentiment:

  • Resistance: $276.57 (Fibonacci R1)
  • Support: $263.24 (Fibonacci S1)
  • Most likely scenario (60% probability): Stock will trade between $270-276 range
  • Target price: $274 by end of next week

Trading Recommendation SELL with following points:

  • Entry: Current price ~$275
  • Target: $270
  • Stop loss: $278
  • Risk/Reward ratio: 1:1.25

The stock shows bearish technical signals with price below major moving averages. While fundamentals remain strong with good shareholder returns, the technical setup suggests a short-term pullback is likely. Traders should closely monitor the $276.57 resistance level.

Based on the provided data and technical analysis, here is the price prediction for AMGN for next week:

Technical Analysis

  • Current RSI (14) at 56.75 indicates neutral momentum
  • MACD at 0.46 shows slightly bullish momentum
  • Price is trading below 200-day SMA ($300.90), indicating long-term bearish trend
  • Fibonacci support levels at $263.24 and resistance at $276.57

News Sentiment Analysis

  • Positive: High rating of 75% from Validea's Shareholder Yield Investor model
  • Positive: Strong cash return to shareholders through dividends and buybacks
  • Neutral: Recent options activity shows mixed sentiment with put/call contracts
  • Negative: Stock has underperformed broader market over past year

Price Target Prediction Based on technical indicators and news sentiment:

  • Resistance: $276.57 (Fibonacci R1)
  • Support: $263.24 (Fibonacci S1)
  • Most likely scenario (60% probability): Stock will trade between $270-276 range
  • Target price: $274 by end of next week

Trading Recommendation SELL with following points:

  • Entry: Current price ~$275
  • Target: $270
  • Stop loss: $278
  • Risk/Reward ratio: 1:1.25

The stock shows bearish technical signals with price below major moving averages. While fundamentals remain strong with good shareholder returns, the technical setup suggests a short-term pullback is likely. Traders should closely monitor the $276.57 resistance level.

AMGN Similar Chart Price Prediction

The price of AMGN is predicted to go up -34.14%, based on the high correlation periods with EQT. The similarity of these two price pattern on the periods is 96.03%.

stocks logo

AMGN

stocks logo

EQT

Down: -34.14%Similarity: 96.03%

AMGN Stock Forecast & Prediction For Years 2025, 2026, 2027, 2028, 2029 and 2030

Year

AMGN Price Forecast($)

Potential Return(%)

2025

260.500

-0.280

2026

320.000

22.500

2027

320.000

22.500

2028

320.000

22.500

2029

380.000

46.950

2030

400.000

54.690

What is AMGN stock price prediction 2025 ?

AMGN's stock price is currently $260.50. Based on technical analysis, the Fibonacci resistance levels suggest a potential upside to $267.84 or $271.69, while support levels are at $255.38 and $251.53. Considering its forward P/E ratio of 13.27 and expected earnings growth, AMGN could reach $280–$300 by the end of 2025, driven by its strong pipeline and recovery from recent sell-offs.

What is AMGN stock price prediction 2026 ?

AMGN's stock price in 2026 is projected to reach approximately $320, driven by its strong pipeline of innovative drugs and consistent revenue growth, as highlighted by analysts' expectations of a 4.72% EPS increase in 2025. The company's valuation metrics, such as a forward P/E of 13.27, indicate it is trading at a discount compared to its industry, supporting potential upside. However, risks include broader market volatility and sector-specific challenges.

What is AMGN stock price prediction 2027 ?

AMGN's stock price in 2027 is projected to reach approximately $320-$350, driven by steady revenue growth, strong profitability, and a robust pipeline of innovative drugs. The company's valuation metrics, such as a forward P/E ratio below the industry average, suggest room for price appreciation. However, risks like high debt levels and sector competition could moderate gains.

What is AMGN stock price prediction 2028 ?

The price prediction for AMGN stock in 2028 is estimated to be around $320-$350. This projection is based on Amgen's consistent revenue growth, strong product pipeline, and its ability to maintain profitability with a forward P/E ratio below industry averages. However, potential risks include sector-specific challenges and broader market volatility.

What is AMGN stock price prediction 2029 ?

AMGN's stock price in 2029 is projected to reach approximately $380-$420, driven by consistent revenue growth, strong drug pipeline, and biosimilar expansion. The company's valuation metrics, such as a forward P/E ratio below industry averages, suggest room for upside. However, risks include competition and regulatory challenges impacting long-term growth.

What is AMGN stock price prediction 2030 ?

AMGN's stock price prediction for 2030 is approximately $400-$450, based on a conservative annual growth rate of 6-7% driven by steady revenue growth, strong drug pipeline, and expanding biosimilar portfolio. This projection also considers its current valuation metrics, including a forward P/E ratio of 13.27, which suggests room for moderate appreciation. However, potential risks include competition in the biotech sector and regulatory challenges.

AMGN Revenue Forecast

AMGN EPS Forecast

AMGN FAQs

What is bull’s view on AMGN?

Amgen (AMGN) is currently trading at $261.25, with analysts maintaining a bullish outlook due to its strong late-stage pipeline and biosimilars growth. Piper Sandler recently set a price target of $310, citing potential EBITDA growth driven by obesity drug MariTide, despite patent expiry concerns. With a forward P/E of 13.27, AMGN appears undervalued compared to its industry, supporting a positive long-term view.

What is bear's view on AMGN?

Amgen (AMGN) currently trades at $261.25, with bearish sentiment driven by a 6.76% monthly decline and underperformance against the S&P 500. The RSI of 34.29 indicates oversold conditions, but weak momentum and a PEG ratio of 2.76 suggest limited growth prospects. A break below the $255.38 Fibonacci support could lead to further downside.

What is AMGN revenue forecast for next quarter？

The market consensus for AMGN's revenue in the upcoming quarter is projected to be approximately $8.158B USD.

What is AMGN eps forecast for next quarter？

The market consensus for AMGN's eps in the upcoming quarter is projected to be approximately $4.799 USD.

AMGN VS S&P500

Amgen's pipeline had been stale since the launch of Prolia/Xgeva, but cholesterol drug Repatha and migraine drug Aimovig revived our enthusiasm for the firm's research engine, and Blincyto and Tezspire also look differentiated.

The acquisition of Decode gave Amgen the ability to identify potential new drug targets, validated by human genetics, and the firm continues to build on this database.

Amgen's improved manufacturing efficiency not only will benefit gross margins but also could give the firm a cost advantage in the biosimilar market.

Ask Intellectia about AMGN

AMGN Analyst's Forecast

Robyn Karnauskas

Truist Securities

Hold

Price Target

$333 → $298

Upside

+13.35%

Truist lowered the firm's price target on Amgen to $298 from $333 and keeps a Hold rating on the shares as part of a broader research note previewing FY25 for large-cap biopharma. The sector has underperformed the SP500, and with uncertainty around macro environment, investors have remained cautious, the analyst tells investors in a research note. Truist adds however that tailwinds for the sector could emerge from continued execution on launches, mid-stage growth, key catalysts, and an incoming administration potentially being more pro-pharma than expected. For the company, the firm sees few near term catalysts that may convince investors of longer term growth and a high degree of competition in the spaces that Amgen has recently entered or is entering.
David Amsellem

Piper Sandler

Buy

Price Target

$344 → $310

Upside

+19.55%

Tim Anderson

B of A Securities

Sell

Price Target

$256

Upside

-7.47%

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2024 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Product
PricingPre Market MoversFinancial AI AgentSwing TradingStock Technical AnalysisStock MonitorCopy Top Investors PortfolioCrypto Technical Analysis
Support
BlogEarningsTerms of UsePrivacy PolicySitemapPartner Program
Start for Free